Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 2,701–2,800 of 2,932
Chayakulkeeree, M., Tan, B. H., Chen, Y., Patel, A., Li, R., Chindamporn, A., Chua, M., Jabeen, K., Lan, N. P. H., Low, L. L., et al. (2025) · Medical Mycology · doi:10.1093/mmy/myaf106 · Cited by 1
Prayekti, E., & Mufarrohah, N. (2025) · Medical Technology and Public Health Journal · doi:10.33086/mtphj.v9i2.7328
Sun, H., Wu, W., Li, X., Deng, Y., Huang, J., Yin, M., & Yan, Z. (2025) · Journal of Fungi · doi:10.3390/jof11110819 · Cited by 1
“As opportunistic pathogens, Candida species primarily infect immunocompromised individuals, including patients with AIDS or cancer and those undergoing antibiotic or chemotherapy treatments [1].”
Duarte, C. K. D. S., da Silva, M. N. P., Santos, M. D. R., Medeiros, V. D. V., Santos, D. C., de Oliveira, A. J., Alexandre‐Moreira, M. S., de Queiroz, A. C., Rosa, L. H., Passarini, M. R. Z., et al. (2025) · Springer eBooks · doi:10.1007/978-3-032-07096-8_10
Haouzi, A. A., Okushi, Y., Shrestha, N. K. M., Gordon, S. M., Fraser, T. G., Elgharably, H., Unai, S., Pettersson, G., Koprivanac, M. J., Griffin, B. P., et al. (2025) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyaf143 · Cited by 2
Antifungal drugs, resistance towards them, and their mechanisms
Sambre, S., Chavan, P., Girse, H., & Gajbhiye, K. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29273-6.00002-3
Potentiating antifungal therapy with nanomaterial strategies for aspergillosis
Ghormade, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29273-6.00012-6
Pabon, A., Sánchez, N., Merikansky-Gerson, S., et al. (2025) · Cureus · doi:10.7759/cureus.98465
“Fungal keratitis (FK) is a severe and potentially sight-threatening corneal infection that remains a major public health problem, especially in tropical and developing regions [1,2].”
Role of 2,3-Dichloro-6-(trifluoromethoxy) Quinoxaline in Combating Candida Infections
Niyazi, H. A., Niyazi, H. A., Helmi, N. R., Juma, N. A., Saleh, B. H., Alqarni, M. A., Mokhtar, J. A., Attallah, D. M., Alkuwaity, K. K., Sait, A. M., et al. (2025) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.19.4.52 · Cited by 1
Bezutti, M. E., Sobiesiak, M. G., da Silva, B. P., & de Quadros, R. M. (2025) · Arquivos de Ciências da Saúde da UNIPAR · doi:10.25110/arqsaude.v30i1.2026-12159
Gruber, D., Walter, J.-C., Bolotnikov, G., Miegel, B., Bierla, E., Bellmann, A., Einsiedler, C. S., Eiblmayr, A. T., Maser, M., Obert, D., et al. (2025) · Virulence · doi:10.1080/21505594.2025.2597576 · Cited by 1
“This transition is particularly dangerous in the form of invasive candidiasis, which is a severe condition associated with mortality rates as high as 55% [13–15].”
High Resolution Computed Tomography in Imaging of Pulmonary Aspergillosis Infection
Khoum, B. L., Borah, P., Nath, R., et al. (2025) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds.v14i4.787
Soni, R., Jadi, R., Sharma, A. K., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10930-6
“Candidemia remains a major cause of morbidity and mortality, especially in hospitalized patients, with a global incidence ranging from 0.33 to 6.51 episodes per 1000 admissions [5].”
InfluentialChen, X., Wang, L., Li, J., Zhang, Y., Liu, C., Yang, J., Shi, J., & Liang, S. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71688
Akhtar, N., Singh, A., Upadhyay, A. K., & Mannan, M. A.-U. (2022) · Figshare · doi:10.6084/m9.figshare.21251875
Bhairavi, V. A., Vidya, S. L., & Sathishkumar, R. (2024) · Figshare · doi:10.6084/m9.figshare.26588607
Kamel, T., & Boulain, T. (2024) · Figshare · doi:10.6084/m9.figshare.26724296
Yao, Q., He, Y., Deng, L., Chen, D., Zhang, Y., Luo, H., & Lei, W. (2024) · Figshare · doi:10.6084/m9.figshare.25434160
Sathyapalan, D. T., Antony, R., Nampoothiri, V., Kumar, A., Shashindran, N., James, J., Thomas, J., Prasanna, P., Sudhir, A. S., Philip, J. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14551970
Fanou, B. A., Klotoé, J. R., Fah, L., Dougnon, V. T., Koudokpon, C. H., Toko, G., & Loko, F. (2020) · Figshare · doi:10.6084/m9.figshare.12986952
Akhtar, N., Singh, A., Upadhyay, A. K., & Mannan, M. A.-U. (2022) · Figshare · doi:10.6084/m9.figshare.21251884
Franconi, I., Rizzato, C., Ghelardi, E., & Lupetti, A. (2024) · Figshare · doi:10.6084/m9.figshare.25538571
Akhtar, N., Singh, A., Upadhyay, A. K., & Mannan, M. A.-U. (2022) · Figshare · doi:10.6084/m9.figshare.21251887
Sathyapalan, D. T., Antony, R., Nampoothiri, V., Kumar, A., Shashindran, N., James, J., Thomas, J., Prasanna, P., Sudhir, A. S., Philip, J. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14551967
Gil, F., Laiolo, J., Bayona-Pacheco, B. L., Cannon, R. D., Ferreira‐Pereira, A., & Carpinella, M. C. (2022) · Figshare · doi:10.6084/m9.figshare.21321440
Szerencsés, B., Igaz, N., Tóbiás, Á., Prucsi, Z., Rónavári, A., Bélteky, P., Madarász, D., Papp, C., Makra, I., Vágvölgyi, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12545081
Yao, Q., He, Y., Deng, L., Chen, D., Zhang, Y., Luo, H., & Lei, W. (2024) · Figshare · doi:10.6084/m9.figshare.26695047
Yao, Q., He, Y., Deng, L., Chen, D., Zhang, Y., Luo, H., & Lei, W. (2024) · Figshare · doi:10.6084/m9.figshare.26695044
Akhtar, N., Singh, A., Upadhyay, A. K., & Mannan, M. A.-U. (2022) · Figshare · doi:10.6084/m9.figshare.21251881
Akhtar, N., Singh, A., Upadhyay, A. K., & Mannan, M. A.-U. (2022) · Figshare · doi:10.6084/m9.figshare.21251878
Kwizera, R., Katende, A., Bongomin, F., Nakiyingi, L., & Kirenga, B. J. (2021) · Figshare · doi:10.6084/m9.figshare.14337667
Self-citationAdditional file 1 of Navigating treatment for basidiobolomycosis: a qualitative review of 24 cases
Pouladfar, G., Jahangiri, S., Shahpar, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26549288
Yao, Q., He, Y., Deng, L., Chen, D., Zhang, Y., Luo, H., & Lei, W. (2024) · Figshare · doi:10.6084/m9.figshare.25434333
Characterizing Candida Species with Distinctive “Feet”-forming Colony Morphology
Aravindh, A., Raj, N., Saha, A., et al. (2025) · Journal of Medical Academics · doi:10.5005/jp-journals-11003-0190
Franconi, I., Tuvo, B., Maltinti, L., FALCONE, M., Mancera, L., & Lupetti, A. (2025) · Journal of Fungi · doi:10.3390/jof12010009 · Cited by 2
“Nowadays, major fungal threats are represented by Candida species and Aspergillus species with an evolving antifungal resistance pattern and are mainly correlated with immunocompromised hosts [2,3].”
Candida glabrata and Fournier\'s Gangrene: A Rare Case
Manjunath, J., Venkategowda, P. M., Singh, J., et al. (2025) · Journal of Acute Care · doi:10.5005/jp-journals-10089-0172
Smart nanotherapeutics against chronic infections
Kumar, A., Singh, A. K., Verma, I. K., Keshri, A., Chauhan, G., Agrawal, S., Ratn, A., Dhakad, M. S., & Sharma, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33070-4.00011-3
Godoy-Martinez, P. C., Muñoz, R. S., Pamela Thomson, M., et al. (2026) · Journal of Fungi · doi:10.3390/jof12010051
“Sporotrichosis is the most prevalent implantation mycosis worldwide, with a global estimate of 40,000 new cases per year [1].”
Reizine, F., Mauget, M., Massart, N., Fédun, Y., Machut, A., Vacheron, C., Savey, A., Friggeri, A., Lepape, A., On behalf of the REAREZO study group, et al. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05391-3
Naziya, B. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1007801 · Cited by 1
Gul, J., Khalid, M., Perveen, S., Awan, A. N., & Mk, S. (2026) · BioNanoScience · doi:10.1007/s12668-025-02359-7
“More than 300,000 cases of invasive aspergillosis, 750,000 cases of candidiasis, and 10,000 cases of mucor-mycosis have been reported in recent years [4 ].”
Three decades of pneumocandin research: Derivatives, structural insights, and strain engineering
Baldia, A., Rajput, D., & Dubey, K. K. (2026) · Bioresource Technology Reports · doi:10.1016/j.biteb.2026.102575
BASICS OF DEVELOPMENT OF NEW ANTIFUNGAL AGENTS IN OPHTHALMOLOGY: A REVIEW
KURGUZOV, I., LOGUNKOVA, I., Бахрушина, Е. О., Durzhinskaya, M. H., Plyukhova, A. A., KURGUZOVA, A., & Narbut, M. N. (2026) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i1.55104
STIS: A novel approach for standardization of spectrometric instruments in fungal Raman spectroscopy
Feng, H., Huang, M., Liang, J., Xu, X., Wang, B., & Xu, J. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.127494
Emerging Frontiers in Clinical Mycology: Innovations, Insights, and Impacts
Apostolopoulou, A., Stewart, A. G., Yoon, H., Steinbrink, J. M., Friedman, D. Z. P., Ostrosky-Zeichner, L. L., & Schwartz, I. S. (2026) · Mycoses · doi:10.1111/myc.70139 · Cited by 1
Miazheinikava, M. O., Litvin, A. A., Kovalev, A. A., Stoma, I. O., & Shlyaga, I. D. (2026) · Health and Ecology Issues · doi:10.51523/2708-6011.2025-22-4-19
Samajdar, S. S., Chatterjee, R., & Mukherjee, S. (2026) · One Health Bulletin · doi:10.4103/ohbl.ohbl_57_25
Bozkurt, İ. (2026) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2026.117284
Kariniotakis, G., Kritsotakis, E. I., Karakonstantis, S., et al. (2026) · Pathogens · doi:10.3390/pathogens15020138
“Over the past two decades, the incidence of invasive fungal infections (IFIs) has escalated, leading to an estimated 3 million cases and 1.6 million related deaths annually worldwide [1].”
InfluentialSchiefermeier-Mach, N., Polleux, J., Heinrich, L., Lechner, L., Levytska, I., Lass‐Flörl, C., & Perkhofer, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341448
Nayak, D., Halagali, P., Gopinathan, A., Ibrahim, R., Aranjani, J. M., Rathnanand, M., & Tippavajhala, V. K. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10376-6
“Yearly, over 150 million severe cases of fungal infections occur world-wide, resulting in 1.7 million deaths [2, 3].”
InfluentialRamos, L. R. D., Ninomiya, D. A., Sequeira, M. F., et al. (2026) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202668008
“17 emphasize these factors as key predictors of AIDS-related morbidity and mortality across African settings.”
Infection and Treatment Protocols in Galleria mellonella for In Vivo Anti-Candida Drug Screening
Campos, L. T., Silva, D. R., Vasconcelos, P. G. S., Silva, J. P. R. E., Santos, V. R. L., Sarmento, L. A., Antonino, E. M. V., Santos, J. D. F., Pereira, J. V., Rosalen, P. L., et al. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6010009
“Although still neglected, fungal infections represent a significant global public health burden, affecting more than one billion people and causing over 1.5 million deaths annually [1].”
Influentialhe, Y., Niu, J., Huang, W., Ju, C., Deng, S., Cui, J., Wang, X., & Zhang, M. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102857 · Cited by 2
“Candida infection is a common and complex clinical challenge, imposing significant health burdens and medical complications world-wide due to the increasing prevalence of immunocompromised conditions [1,2].”
Zhang, S., Cheng, J., Zhou, G., & Wang, J. (2026) · Biophysical Chemistry · doi:10.1016/j.bpc.2026.107591
Langa, J. C., Moon, T. D., Sacarlal, J., & Sidat, M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340217
“…that, the quality of health care delivered to patients has largely received little attention in LMICs [20] Additionally, a large proportion of patients with opportunistic infections and advanced HIV disease are rarely reported, mainly due to a lack of diagnostic and human resource capacity [15,21].”
Inclán, M., Clares, M. P., Álvarez-Duarte, E., Fernández‐Silva, F., Salas, V., Guarro, J., Chicote, J. U., Verdejo, B., Delgado‐Pinar, E., García‐España, E., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c09700
Anuar, N. S., Yusof, N. Y., Zainol, D. A., & Rahumatullah, A. (2025) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2025.033.3.15
Singh, S., Garg, P., Srivastava, P., & Trivedi, M. (2025) · Toxicology International · doi:10.18311/ti/2025/v32i2/48150
In Silico Analysis of Active Compounds of Peruvian Medicinal Plants with Antifungal Activity
Torre, V. E. V.-L., López-Gamboa, J. A., Espinoza-Chávez, R. M., & Chávez‐Fumagalli, M. Á. (2026) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-026-00737-0
“At the same time, recent studies estimate that they kill more than 1.6 million people each year, with nearly 4.9 million people worldwide being affected annually by invasive or chronic infections (Bongomin et al. 2017; Janbon et al. 2019).”
InfluentialHan, Y., Li, Y., Liu, Z., et al. (2026) · JTCVS Open · doi:10.1016/j.xjon.2026.101688
“Postoperative complications occurred in 14 patients (18.9 % ) in the aspergillosis group and 10 patients (43.5 % ) in the mucormycosis group ( P = .017).”
InfluentialComparing the anti-Candida albicans effect of Zingiber officinale with common antifungal drugs
Gavanji, S., Bakhtari, A., Baghshahi, H., Chamgordani, Z. H., Gavanji, J., Sinaei, J., & Hassani, D. (2025) · THE NEW ARMENIAN MEDICAL JOURNAL · doi:10.56936/18290825-3.19v.2025-30 · Cited by 2
Hadi, M. K., AL‐Janabi, A. A. H. S., & Abdulwahid, H. H. (2026) · Microbiology and Biotechnology Letters · doi:10.48022/mbl.2512.12016
Girase, H., Narwade, M., Alsayari, A., Wahab, S., Kesharwani, P., & Gajbhiye, K. R. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104222
Xisto, M. I. D. D. S., Rollin‐Pinheiro, R., da Rosa, P. C. M., Santos, J. D. S., Irmão, N. F. D. S., Abib, J. A. A., Rochetti, V. P., de Castro-Almeida, Y., Freitas, G. M. P. D. S., Cypriano, J. B. S., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03356-25 · Cited by 2
“Opportunistic fungal infections have been increasingly reported since the 1990s, whose pathogens have been presenting high virulence and resistance to antifungal drugs (1, 6, 7).”
Saha, A., Goswami, M., Banerjee, S., Ghosh, A., Chatterjee, S. S., & Sarkar, K. (2026) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2026.117346 · Cited by 1
Global asthma and pest control: bugs and WASPs
Shah, P. A., Diver, S. E., & Brightling, C. E. (2026) · Thorax · doi:10.1136/thorax-2026-224743
Plant-based antifungal peptides: novel therapeutic compounds against emerging fungal pathogens
Ahmedi, S., Mirza, U., & Manzoor, N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15652-6.00010-2
Plant-based bioactive peptides: pharmaceuticals, nutraceuticals, and herbal drugs
Singh, A., & Parmar, A. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15652-6.00004-7
Jiang, Q., Zeng, X., Zhang, Q., Yang, F., Lv, T., Zhang, Y., Wang, J., Li, F., & Xu, D. (2026) · BMC Microbiology · doi:10.1186/s12866-026-04881-4
“According to epidemiological data, fungal infections affect over one billion individuals worldwide [1].”
Ebong, S. M. A., Kengne, V. N., Ayong, M. N. A., Foko, L. P. K., Ambono, J. L. N., Ndzana, G. M., Baïdam, M. T., Youguitcha, O., Ziem, O., Ayangma, C. R., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12990-8
Borba-Santos, L. P., & Rozental, S. (2026) · Pharmaceuticals · doi:10.3390/ph19030479
“Fungal infections are one of the leading causes of infectious disease-related deaths worldwide [1,2].”
Yang, M., He, X., Lu, Q., Bian, X., Fang, J., & Ding, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1693726
“(3, 4).”
Kamwiziku, G. K., Batumbo, D. B., Éric, K. I., Mandja, B.-A. M., Mwenebitu, D. L., Batoko, B., Mbewo, F., Binangu, M., Barhayiga, B. N., Situakibanza, H., et al. (2026) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2026.101620
Self-citationÇevik, P. K. (2026) · Bitlis Eren Üniversitesi Fen Bilimleri Dergisi · doi:10.17798/bitlisfen.1863965
Rare fungal keratitis caused by plant pathogens: report of two cases and review of the literature
Zhao, Z., Xiang, L., Liu, Y., Xu, S., Chen, Y., & Yu, M. (2026) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2026.1785252
Fongémies : épidémiologie, diagnostic et conduite à tenir
Dellière, S., Chantelot, L., Garnaud, C., & Cornet, M. (2026) · EMC - Biologie Médicale · doi:10.1016/s2211-9698(25)48322-8
Zhang, W., Liu, Y., Guo, S., & Yu, S. (2026) · Pest Management Science · doi:10.1002/ps.70738
Strain-Dependent Protective Innate Immunity Against Pneumocystis Pneumonia in Mice
Inzerillo, P. C., Gigliotti, F., & Wright, T. W. (2026) · Journal of Fungi · doi:10.3390/jof12040239
Pinheiro, M. J. F., Parker, J. E., Ferreira, M. T., Fernandes, F., & Mira, N. P. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03344-25
“Invasive and mucosal candidiasis are typically caused by Candida albicans , but infections caused by N. glabratus (formerly classified as Candida glabrata ) are increasingly frequent, especially in Europe and North America (1, 2, 4).”
Steixner, S. J. M., Vahedi‐Shahandashti, R., Eisele, D., Ruppitsch, W., & Lass‐Flörl, C. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1771561
“The healthcare-associated burden offungal infections continues to rise, signi fi cantly contributing to morbidity and mortality among hospitalized patients worldwide (Bongomin et al., 2017; Rayens and Norris, 2022; Cornely et al., 2025).”
Chitosan/silver/hyaluronic acid as a novel nanocomposite against Candida Spp.
Jaafar, F. K., Taha, A. A., & Ismail, R. A. (2026) · AIP conference proceedings · doi:10.1063/5.0318731
Surgery for Pulmonary Aspergillosis
Neto, J. D. S. M., Costa, A. N., & Stilles, B. (2026) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2026.02.013
An Efficient Workflow for Fungal Nucleic Acid Detection in Sputum
Han, Y. M., Tang, D., Gao, Y., Ji, L., Hu, J., & Gong, Y. (2026) · Journal of Fungi · doi:10.3390/jof12040252
“It is estimated that over 150 million individuals worldwide are afflicted with IFIs [2,3], resulting in more than 1.6 million deaths annually [4].”
InfluentialSelf-assembly into functional amyloids of Aspergillus fumigatus hydrophobins
de Francisco, B. R. (2019) · theses.fr (ABES) · doi:10.70675/6d4509a4z523az402bz88c2z23825bd41981 · Cited by 1
Scedosporium et son environnement : étude des mécanismes d'adaptation
Poirier, W. (2020) · theses.fr (ABES) · doi:10.70675/666af517z8b82z41f5z84c6z94ea1386b7c1 · Cited by 1
Developing a novel antifungal strategy by targeting an epigenetic reader domain
Wei, K. (2020) · theses.fr (ABES) · doi:10.70675/ce7dc30ezfb21z43adz8835zf9a2e73daf67
Environmental adaptation of Candida albicans : the examples of persistence and chlamydosporulation
Denega, I. (2020) · theses.fr (ABES) · doi:10.70675/748584ddzf6f4z4124z9237z56d0535d3352
Couttenier, E. (2020) · theses.fr (ABES) · doi:10.70675/402f3bf1zd527z43acz9758z57e168d6e67e · Cited by 1
Structural characterization of fungal cell walls architecture by solid-state NMR
Lamon, G. (2020) · theses.fr (ABES) · doi:10.70675/c5c0354az3df6z4041zbbafz4d7be0c50c45 · Cited by 2
Épidémiologie et sensibilité aux antifongiques des espèces cryptiques d’Aspergillus
Imbert, S. (2020) · theses.fr (ABES) · doi:10.70675/5c53243czfcb2z44aezae70z0d7c0f2806be
Biomarkers in the Diagnosis of Aspergillosis
Agudelo, L. R., Cáceres, D. H., Rincón, J. C. A., Jaramillo, J. C., Zuluaga, A., & Rúa-Giraldo, Á. L. (2026) · Journal of Fungi · doi:10.3390/jof12040259 · Cited by 1
Blandenet, M. (2022) · theses.fr (ABES) · doi:10.70675/e0b5fe74z86f9z469dzb77bz0812df00267d · Cited by 1
Influence of the microbiota on Candida albicans gastrointestinal colonization in healthy individuals
Delavy, M. (2023) · theses.fr (ABES) · doi:10.70675/da5a2f9dz2e64z4e1fz9280z36a010c349be
Amélioration de la prise en charge diagnostique des infections fongiques systémiques
Menu, E. (2022) · theses.fr (ABES) · doi:10.70675/f42e6ff4ze638z4796z9c8fz1f178e8942c3
Fonctions et biosynthèse des β-1,6-glucanes de la paroi cellulaire chez Candida albicans
Bekirian, C. (2024) · theses.fr (ABES) · doi:10.70675/b1028289z0c26z4acaz8f96z18e5c0c94464
Kharrat, O. (2025) · theses.fr (ABES) · doi:10.70675/c47e5b02ze7d4z4d9cz9fd6z03e321b9669f
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.